Johnson & Johnson has decided to discontinue the development of aticaprant for major depressive disorder due to insufficient efficacy. Despite setbacks, J&J remains focused on exploring aticaprant's potential in other high-need areas and aims to become a leading neuroscience company by 2030.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing